Enanta Pharmaceuticals, Inc. (ENTA)

Enanta Pharmaceuticals Cash Flow Statement

Financials in millions USD. Fiscal year is October - September.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Sep 30, 2025	Sep 30, 2024	Sep 30, 2023	Sep 30, 2022	Sep 30, 2021
Net Income	-81.89	-116.05	-133.82	-121.76	-79
Depreciation & Amortization	4.59	2.34	2.37	2.97	3.33
Loss (Gain) From Sale of Assets	0.01	0.02	0.15	-	-
Loss (Gain) From Sale of Investments	0.5	-1.14	-2.93	0.33	-1.91
Stock-Based Compensation	18.57	26.8	28.22	26.97	20.99
Other Operating Activities	-0.95	2.14	-5.17	-0.08	0.28
Change in Accounts Receivable	-0.24	1.97	11.7	3.26	-0.08
Change in Accounts Payable	-1.31	-0.41	-1.15	-4.63	3.77
Change in Income Taxes	32	-1	-2.29	8.54	-24.21
Change in Other Net Operating Assets	9.46	6.57	-0.24	-0.37	6.84
Operating Cash Flow	-19.27	-78.76	-103.15	-84.78	-70
Capital Expenditures	-12.9	-17.95	-9.06	-2.13	-0.75
Investment in Securities	53.24	76.18	-44.52	57.02	37.74
Investing Cash Flow	40.35	58.24	-53.58	54.9	36.99
Issuance of Common Stock	0.15	0.15	2.21	21.26	3.61
Other Financing Activities	-26.76	-27.77	195.92	-1.23	-0.53
Financing Cash Flow	-26.62	-27.63	198.13	20.03	3.08
Net Cash Flow	-5.54	-48.16	41.39	-9.85	-29.93
Free Cash Flow	-32.17	-96.71	-112.21	-86.91	-70.75
Free Cash Flow Margin	-49.24%	-142.99%	-141.67%	-100.87%	-72.88%
Free Cash Flow Per Share	-1.51	-4.57	-5.35	-4.22	-3.51
Cash Interest Paid	8.79	11.71	1.99	-	-
Cash Income Tax Paid	-33.68	0.24	4.9	-	0.03
Levered Free Cash Flow	-18.54	-71.38	-62.34	-42.08	-57.67
Unlevered Free Cash Flow	-13.74	-64.55	-59.13	-42.08	-57.67
Change in Working Capital	39.91	7.13	8.02	6.79	-13.69

Updated Sep 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q